| Literature DB >> 34959729 |
Lorenzo Di Cesare Mannelli1, Fortunato Palma Esposito2, Enrico Sangiovanni3, Ester Pagano4, Carmen Mannucci5, Beatrice Polini6, Carla Ghelardini1, Mario Dell'Agli3, Angelo Antonio Izzo4, Gioacchino Calapai5, Donatella de Pascale2, Paola Nieri6,7.
Abstract
Marine pharmacology is an exciting and growing discipline that blends blue biotechnology and natural compound pharmacology together. Several sea-derived compounds that are approved on the pharmaceutical market were discovered in sponges, marine organisms that are particularly rich in bioactive metabolites. This paper was specifically aimed at reviewing the pharmacological activities of extracts or purified compounds from marine sponges that were collected in the Mediterranean Sea, one of the most biodiverse marine habitats, filling the gap in the literature about the research of natural products from this geographical area. Findings regarding different Mediterranean sponge species were individuated, reporting consistent evidence of efficacy mainly against cancer, infections, inflammatory, and neurological disorders. The sustainable exploitation of Mediterranean sponges as pharmaceutical sources is strongly encouraged to discover new compounds.Entities:
Keywords: Mediterranean Sea; Mediterranean sponges; anti-inflammatory; antimicrobials; antiproliferative; blue biotechnology; marine natural products; marine pharmacology
Year: 2021 PMID: 34959729 PMCID: PMC8715745 DOI: 10.3390/ph14121329
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Number of accepted aquatic sponge in the world.
| Name | Acc. Species | Acc. Species Marine | Acc. Species Fresh |
|---|---|---|---|
| Phylum: Porifera | 9436 | 9174 | 264 |
| Class: Calcarea | 801 | 801 | 0 |
| Class: Demospongiae | 7817 | 7555 | 264 |
| Class: Hexactinellida | 687 | 687 | 0 |
| Class: Homoscleromorpha | 130 | 130 | 0 |
acc. species: the number of accepted species within the specific rank; acc. species marine: number of accepted marine species within the specific rank; acc. species fresh: number of accepted freshwater species within the specific rank.
Figure 1Sponge families that are present in the Mediterranean Sea.
Figure 2Mediterranean sponges grouped by geographical localization.
Figure 3Graphical representation of sponge activity reports for the therapeutic category. The size of the bubble is proportional to the number of papers individuated.
Health beneficial properties of Mediterranean sponges.
| Sponge | Extract/ | In Vitro/ | Effect | Active Dose/ | Reference |
|---|---|---|---|---|---|
|
| Methanol extract | In vitro: LAN5 and SK-N-BE(2)-C cells | Anticancer | 10–20 ppm significantly increased cell death | [ |
| Oroidin, 2-cyano-4,5-dibromopyrrole | In vitro: KB, Lu1, KB-V, LNCaP, ZR-75-1 cells | Anticancer | Only 2-cyano-4,5-dibromopyrrole: IC50 = 1.7–10.8 µg/mL | [ | |
| Ethyl acetate extract, Mixture of brominated pyrrole alkaloids | In vitro: | Antimicrobial | 7–18 mm inhibition zone (5 mg/disk for bacteria and 10 mg/disk for yeasts) | [ | |
|
| Zarzissine | In vitro: P-388, KB, NSCLC-N6 cells | Anticancer | IC50 = 5–12 µg/mL | [ |
|
| Aeroplysinin-1; | In vitro: SH-SY5Y, MCF-7 cells | Anticancer | IC50 about 5 µM for aeroplysinin-1 on SH-SY5Ycells; | [ |
| Isofistularin-3 | In vitro: RAJI, U-937, JURKAT, K-562, MEG-01, HL-60, SH-SY5Y, PC-3, MDA-MB-231 cells | Anticancer | IC50 = 8.1–50 μM | [ | |
| Methanol extract, Aeroplysinin-1 | In vitro: | Antimicrobial | 8–30 mm inhibition zone (100 μg/disc) | [ | |
|
| Damipipecolin and damituricin | In vitro: rat neurons | Reversion of the increase of [Ca2+] induced by serotonin | IC50 = 0.1 µg/mL | [ |
| Ethyl acetate extract, Mixture of brominated pyrrole alkaloids | In vitro, | Antimicrobial | 7–26 mm inhibition zone (5 mg/disk) | [ | |
|
| Alkaloids | In vitro: rat neurons | Reversion of the increase of [Ca2+] induced by serotonin, glutamic and quisqualic acid | IC50 = 10 µg/mL | [ |
| Methanol extract, Hymenialdisine, 10- E-Hymenialdisine, Spongiacidine B | In vitro, | Antimicrobial | >20 mm of inhibition zone (concentration not determined) | [ | |
|
| Marine collagen hydrolysates | In vitro: L929 and HaCaT cells | Enhanced proliferation of fibroblasts and keratinocytes; | IC50 = 10, 50, or 100 µg/mL | [ |
| Proteic P4 fraction (from a crude extract) containing Chondrosin | In vitro: L929, RAW 264.7, MDA-MB-468 and HeLa cells | Anticancer | 1–100 µg/mL | [ | |
|
| CH2Cl2/MeOH extract, Clathridimine, clathridine, clathridine zinc complex, preclathridine | In vitro, | Antimicrobial | 11–38 mm inhibition zone (concentration not determined) | [ |
|
| Crambescidin 816 | In vitro/ex vivo, | (1) Cytotoxicity against colon cells; | (1) IC50 = 0.24 ug/mL; | [ |
| Crambescidin 816, 844 and 800 | In vitro: L-1210 cells | Anticancer | 98% cytotoxicity at 0.1 µg/mL | [ | |
| Crambescidin 816, 830 and 800 | In vitro: HepG2 | Anticancer | IC50 = 0.18–2.66 μM | [ | |
|
| P3 compound | In vitro: U-2 OS cells | Anticancer | IC50 = 6.6 μM | [ |
|
| Avarol | In vivo, mouse | Reduction of paw edema | ED50: 9.2 mg/kg (orally) and 97 μg/ear (topically) | [ |
| Avarol | In vitro, human recombinant enzyme | Inhibition of human recombinant synovial PLA2 activity | IC50: 158 μM | ||
| Avarone | In vivo, mouse | Reduction of ear edema | ED50: 4.6 mg/kg (orally) and 397 µg/ear (topically) | ||
| Avarol and avarone | In vitro, human leukocytes | Inhibition of LTB4 and TXB2 release | IC50: 0.6 and 0.8 μM (LTB4); IC50 1.4 and 3.3 μM TXB2) | ||
| Etanolic extract | In vitro: K562, KMS-12PE, A549, A375, H929, MCF7, HeLa, HCT116 cells | Anticancer | IC50 = 2.91–25.15 µg/mL; | [ | |
| Avarol | HT-29 cells | Anticancer | IC50 = <7 μM | [ | |
| Avarol; | In vitro: L5178y cells | Anticancer | IC50 = 0.93 μM (avarol) and 0.62 μM (avarone) | [ | |
| Avarol; | In vitro: L1210, Raji C8166 cells | Anticancer | IC50 = 9.2–18.1 μM | [ | |
| Avarol; | In vitro: HCT116 H4IIE cells | Anticancer | Avarone most potent: IC50 = 5.3–5.5 μM | [ | |
| Avarol | In vitro: | Antimicrobial | MIC and MFC: 0.8–12 µg/mL | [ | |
|
| Carvenolide | In vitro, human recombinant enzyme | Inhibition of human synovial PLA2 | IC50: 8.8 μM | [ |
| In vitro, human macrophages | Reduction of TNF-α, nitrite and PGE2 production | 4.9 μM (TNFα); 7.7 μM (nitrite); IC50: 9.3 μM (PGE2) | |||
|
| MeOH fraction | In vitro: MCF-7, MDA-MB231, and MDA-MB468 | Anticancer | IC50 = 44–80 µg/mL | [ |
|
| Butanolic extract, Fulvynes A-I | In vitro, chloramphenicol-resistant | Antimicrobial | IC50: 60–12 µM | [ |
|
| Panicein A hydroquinone | In vitro: MeWo cells | Anticancer | Panicein A: IC50 = >30 µM | [ |
|
| Palinurin | In vitro, neuroblastoma SH-SY5Y cells | rGSK-3b inhibitory activity | IC50 = 2.6 µM | [ |
|
| Polyprenyl-1,4-hydroquinone derivates | In vitro: H4IIE cells | Anticancer | Heptaprenyl | [ |
|
| Polyprenyl-hydroquinones; furanoterpenoids | In vitro: Inhibition of CDC25 phosphatase | Anticancer | 4-OH-3 Tetraprenylphenylacetic acid: IC50 = 0.4–4 µM; | [ |
|
| Polyprenyl-hydroquinones; furanoterpenoids(Bodrum, Turkey; Naples, Italy; Sutomiscica, Croatia) | In vitro: Inhibition of CDC25 phosphatase | Anticancer | 4-OH-3 Tetraprenylphenylacetic acid: IC50 = 0.4–4 µM;2-Octaprenylhydroquinone: IC50 = 400 µM | [ |
|
| IS2, IS3 | In vitro: human recombinant enzyme | Inhibition of synovial PLA2 | IC50: 48.7 and 48 µM | [ |
| In vitro: human neutrophils | Inhibition of LTB4 production and TXB2 synthesis and release | IC50: 23.1 and 7.4 µM (LTB4); IC50 3.9 and 3.4 µM (TXB2) | |||
| In vivo, mouse | Reduction of ear inflammation | 250 µg/ear and 125 µg/ear (topically) | |||
|
| Methanol extract | In vitro: LAN5 and SK-N-BE(2)-C cells | Anticancer | 10–20 ppm significantly increased cell death | [ |
|
| Topsentin B1 and B2 | In vitro: NSCLC-N6 cells | Anticancer | IC50 = 6.3 (B1) and 12 (B2) µg/mL | [ |
|
| Paniceins A, Panicein B3, Panicein C | In vitro: CCRF-CEM, NCI-H522 | Anticancer | −log10 I50: 5.11–5.48 | [ |
|
| 3-Alkylpyridinium polymers | In vitro, isolated enzyme | AChE inhibition | 50% inhibition induced by 0.06 (human erythrocyte AChE), 0.08 (electric eel AChE), 0.7 (insect recombinant AChE) and 0.14 µg/mL (horse serum butyrylcholinesterase) | [ |
| 3-Alkylpyridinium oligomers and polymers | Ex vivo, mouse skeletal muscle | AChE inhibition; | IC50 = 18.5 μM (mouse muscle twitch), 18.5 μM (tetanic contraction) | [ | |
|
| Furanosesterterpene tetronic acids and Polyprenyl-hydroquinones | In vitro: | Anticancer | Furanosesterpene tetronic acids IC50=> 80 µM; Polyprenyl-hydroquinones IC50 = 3–23 µM | [ |
|
| Furanosesterterpene tetronic acids and Polyprenyl-hydroquinones | In vitro: | Anticancer | Furanosesterpene tetronic acids IC50 => 80 µM; Polyprenyl-hydroquinones IC50 = 3–23 µM | [ |
|
| Polyprenyl-1,4-hydroquinone derivates | In vitro: H4IIE cells | Anticancer | Heptaprenylhydroquinone: IC50 = 2.5 μM | [ |
|
| Hydroxylated nonaprenylhydroquinone; | In vitro: K562 cells | Anticancer | Hepta- and octa-prenylhydroquinone: 8 and 10 µM; Hydroxylated nonaprenylhydroquinone 193 µM | [ |
| Furanosesterterpene tetronic acids and Polyprenyl-hydroquinones | In vitro: | Anticancer | Furanosesterpene tetronic acids IC50 => 80 µM; Polyprenyl-hydroquinones IC50 = 3–23 µM | [ | |
|
| Methanol and fractions | In vitro: A549, HCT15, MCF7 cells | Anticancer | F3 fraction greater potency: | [ |
| Furospongin-5; Cyclofurospongin-2; | In vitro: P-388 cells | Anticancer | Furospongin: IC50 = 5 µg/mL | [ | |
| Polyprenyl-hydroquinones; furanoterpenoids | In vitro: Inhibition of CDC25 phosphatase | Anticancer | 4-OH-3 Tetraprenylphenylacetic acid: IC50 = 0.4–4 µM; | [ | |
| Methanol/water, crude extract and fractions | In vivo, mice | Anticovulsant and analgesic | 600 mg/kg crude extract; 100 and 200 mg/kg 50% methanol fractions | [ |
Figure 4Structures of the molecules that have been isolated from Mediterranean sponges.